Amy Murnane is the Vice President of Project Management at Palladio Biosciences. Amy has been in the pharmaceutical/biotech industry for over 30 years having held senior leadership positions in drug discovery and development at SmithKline Beecham/GlaxoSmithKline, Genentech, Integral Health, and Vitae Pharmaceuticals. Over her career, Amy has led transnational line organizations in CMC and portfolio/project management, and global matrix teams covering oncology, antimicrobial, musculoskeletal, dermatology, hematology, cardiovascular and immune-mediated inflammatory disease areas.
Amy was recently working at Integral Health, leading the portfolio, project management and diligence activities for clinical assets. Prior to joining Integral Health, she led the GSK Enterprise R&D Data Integrity Risk Strategy as Enterprise Risk Owner for pharma, vaccines, and consumer health R&D data integrity. Prior to this position, Amy was Vice President of Virtual Development in the Virtual Proof of Concept Discovery Performance Unit (VPoC DPU) in GSK Pharma, providing strategic leadership, project leadership, project management, budget management, and compliance oversight for VPoC’s portfolio spanning target identification through Phase II in the clinic. As a founding member of the VPoC DPU, Amy was involved in the design and implementation of the VPoC business operating model (a fully outsourced model from target identification through Phase II clinical development) to deliver low cost, high quality commit-to-medicine development assets via an outsourcing strategy, Ex-US/EU, based on an full time equivalent and fee for service basis.
Prior to VPoC, Amy was Vice President of Project Management at Vitae Pharmaceuticals, leading project teams for dermatology, oncology, and cardiovascular assets in clinical development.
Prior to Vitae, Amy held several R&D roles, including Therapeutic Area Project and Portfolio Management Head for Microbial Musculoskeletal and Proliferative diseases in GSK (responsible for overseeing a portfolio of 54 programs/projects and more than100 clinical trials), Head of Biopharmaceutical Development for SmithKline Beecham, and Group Leader for Cell Culture and Fermentation R&D at Genentech, including CMC Leader for Herceptin®, TPO,TGF-β and second generation TPA.
Amy has led/contributed directly to the development of five marketed products in numerous therapeutic areas, including Herceptin®.
Amy received her PhD in Biochemistry from Dartmouth College.